Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy

Ayaka Wakatsuki

Kristel Van Calsteren, MD PhD

Elyce Cardonick, MD

Mina Mhallem

Frederic Amant, MD, PhD

Kristel Van Calsteren, MD, PhD

Lieven Lagae, MD, PhD

Luc Mertens, MD, PhD

Kristel Van Calsteren, MD

Michael Halaska, MD

Monica Fumagalli, MD PhD

Maarten Lambrecht, MD PhD

Jaroslav Klát, MD

Lone Storgaard, MD

Berit Woetmann Pedersen, MD

Mona Aarenstrup, MD

Cristel Maria Soerensen-Hjortshoej, MD

Georeg-Marios Makris, MD

Fedro Peccatori, MD

Monica Fumagalli, MD

Giovanna Scarfone, MD

Giorgia Mangili, MD

Bianca Masturzo, MD

Álvaro Cabrera Garciá, MD

Ingrid Boere, MD PHD

Frédéric Amant, MD PHD

C.A.R. Lok, MD PHD

M.M. Van den Heuvel-Eibrink, MD PHD

C.J.M. De Groot, MD PHD

R.C. Painter, MD PHD

P.B. Ottevanger, MD PHD

P.O. Witteveen, MD PHD

C.P. Schröder, MD PHD

S.J. Gordijn, MD PHD

J. Kroep, MD PHD

R.L.M. Bekkers, MD PHD

A.M.J. Thijs, MD PHD

Line Bjorge

Kolawa Wojciech

Marta Balajewicz-Nowak, MD

Kazimierz Pitynski, MD

Stefan Sajdak, MD

Paula Duarte, MD

Anastasia Parokonnaya, MD

Roman Shmakov, MD

Vladim Bezrukikh

Kenny Rodriguez-Wallberg, MD

Amant Frederic, MD PhD

The researchers aim to investigate the outcome (overall survival) of mothers who are diagnosed and/or treated for cancer during pregnancy. Furthermore they want to test the hypothesis that children who were exposed to cancer or cancer treatment (cytotoxic drugs, radiation therapy, targeted therapy,...) develop normally (neurologic and cardiologic examination).

Study contains several study parts (protocol version 4.4):

\*\*\*\*\*\*\*\*\*\*Part I. Pregnancy, delivery and maternal health\*\*\*\*\*\*\*\*\*\* Part I.I.A. Registration study 'Cancer during pregnancy' mother and neonate None Part I.I.B. Effects of prenatal exposure to cancer treatment on fetal growth. The association between placental pathophysiologic mechanisms (histopathology and immunohistochemistry), circulating maternal factors and fetal growth.

From participating women, a maternal blood sample will be collected during or shortly after birth. Also, an umbilical cord blood sample and placental and umbilical cord biopsies will be drawn.

Part I.II. Measurement of maternal and paternal anxiety and emotional needs when confronted with a cancer diagnosis during pregnancy The participants will be asked to complete questionnaires.

\*\*\*\*\*\*\*\*\*\*Part II. Child\*\*\*\*\*\*\*\*\*\* Long term follow up of children and adolescents in utero exposed to chemotherapy and/or radiotherapy Regular check-ups of the child, at the age of 6 months, 18 months, 3y, 6y, 9y, 12y, 15y, and 18y, and after the age of 18 years: 5-yearly cardiologic assessment and questionnaires (23y, 28y, 33y, 38y, and 43y). Optional at the ages of 9y, 12y, 15y and 18y: MRI session.

Summary part I:

Prospectively the outcome of mothers diagnosed and/or treated for cancer during pregnancy will be registered and investigated.

Summary Part II:

In a prospective trial we invite children that were exposed to cytotoxic drugs or radiotherapy in utero for a standardized neurological and cardiological examination. The examinations will be done by qualified psychologists, neurological and cardiological pediatricians.

Maternal blood serum and sediment of blood; from 2010 on we collect umbilical cord blood.

Since new approval of protocol version 4.2 (08-02-2018) we collect samples of placental tissue, umbilical cord tissue and membranes.

Effects of Oncological Treatment During Pregnancy on Mother and Child

Oncological Treatment During Pregnancy: Pharmacokinetics of Chemotherapy and Long Term Follow up of the Offspring

Spots Global Cancer Trial Database for chemotherapy and radiotherapy during pregnancy